Compare IMVT & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | CELH |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.4B |
| IPO Year | 2019 | 2008 |
| Metric | IMVT | CELH |
|---|---|---|
| Price | $38.35 | $29.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | $33.00 | ★ $64.81 |
| AVG Volume (30 Days) | 951.3K | ★ 7.3M |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $1,318,014,000.00 |
| Revenue This Year | N/A | $37.04 |
| Revenue Next Year | N/A | $9.89 |
| P/E Ratio | ★ N/A | $87.96 |
| Revenue Growth | N/A | ★ 101.65 |
| 52 Week Low | $14.32 | $26.54 |
| 52 Week High | $41.23 | $66.74 |
| Indicator | IMVT | CELH |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 48.20 |
| Support Level | $37.53 | $27.39 |
| Resistance Level | $41.22 | $33.84 |
| Average True Range (ATR) | 1.47 | 1.20 |
| MACD | -0.38 | 0.04 |
| Stochastic Oscillator | 33.86 | 57.22 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.